Market Research Reports and Industry Reports

Rituximab biosimilar

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnsons Remicade, which is approved for RA, Crohns disease and several other conditions and had $2 billion in sales in Europe last year. This approval has further increase the optimism of companies developing and marketing biosimilars and the wait for the launch of others in queue Rituxan, Herecptin, Enbrel etc may not be too long. These three drugs alone had worldwide sales of ~$21b in 2012.

Commercial success of biosimilars will be depend both on affordability and accessibility assuming that the copy molecule is at par on efficacy, safety and similarity with the branded product. Uptake and marketing strategy of Remicade biosimilar will be closely watched by investors as well as companies developing/marketing Biosimilars. In this report, we have analyzed the market opportunity of rituximab biosimilar.
Table 1
Rituxan/MabTheras Biosimilar
BIOLOGICS PATENT EXPIRY TILL 2017
Table 2
Rituxan/MabTheras Biosimilar
BIOSIMILAR PIPELINE
Table 3
Rituxan/MabTheras Biosimilar
PRICE DIFFERENCE BETWEEN REFERENCE PRODUCTS AND BIOSIMILARS
Table 4
Rituxan/MabTheras Biosimilar
RITUXIMAB PATENT EXPIRIES
Table 5
Rituxan/MabTheras Biosimilar
PROJECTED RITUXIMAB SALES TILL 2017
Table 6
Rituxan/MabThera_Biosimilar
COMPETITION FROM KEY MARKETED DRUGS
Table 7
Rituxan/MabTheras Biosimilar
EFFICACY TARGET PROFILE OF GA101 IN CLINICAL STUDIES
Table 8
Rituxan/MabTheras Biosimilar
OBINUTUZUMAB: PHIII CLINICAL STUDY
Table 9
Rituxan/MabTheras Biosimilar
OBINUTUZUMAB: PHI/II CLINICAL STUDY
Table 10A
Rituxan/MabTheras Biosimilar
RITUXIMAB DEVELOPMENT PROGRAMS - IMMUNOLOGY
Table 10B
Rituxan/MabTheras Biosimilar
RITUXIMAB DEVELOPMENT PROGRAMS - ONCOLOGY
Table 11
Rituxan/MabTheras Biosimilar
COMPETITIVE LANDSCAPE RITUXIMAB
Table 12
Rituxan/MabTheras Biosimilar
SELECT RA DRUGS IN DEVELOPMENT
Table 13
Rituxan/MabTheras Biosimilar
ANALYTICAL ATTRIBUTES FOR CHARACTERIZATION OF BIOSIMILAR
Table 14
Rituxan/MabTheras Biosimilar
FDA APPROVED PRODUCTS USING ANIMAL/YEAST ALTERNATIVE EXPRESSION SYSTEM
Table 15
Rituxan/MabTheras Biosimilar
MABS EVOLUTION OF TECHNOLOGIES- FROM MOUSE TO HUMAN

List Of Tables

Figure 1
Rituxan/MabTheras Biosimilar
WORLDWIDE SALES
Figure 2
Rituxan/MabTheras Biosimilar
REDITUX: NOT A PROVEN BIOSIMILAR
Figure 3
Rituxan/MabTheras Biosimilar
SALES OF RITUXAN/MABTHERA 2000-2009
Figure 4
Rituxan/MabTheras Biosimilar
ANTIBODIES PRODUCED IN CHO
Figure 5A
Rituxan/MabTheras Biosimilar
CHARACTERIZATION OF COMMERCIAL BATCHES - RITUXAN
Figure 5B
Rituxan/MabTheras Biosimilar
CHARACTERIZATION OF COMMERCIAL BATCHES - RITUXAN
Figure 6
Rituxan/MabTheras Biosimilar
REGULATORY GUIDANCE FOR BIOSIMILAR
Figure 7
Rituxan/MabTheras Biosimilar
BIOSIMILARS MARKET SHARE IN EU
Figure 8
Rituxan/MabTheras Biosimilar
INCIDENCE OF NHL BY COUNTRY
Figure 9
Rituxan/MabTheras Biosimilar
RITUXAN/MABTHERA SALES 2011
Figure 10
Rituxan/MabTheras Biosimilar
ROCHE STARTEGY FOR MABTHERA IN EU
Figure 11
MabTheras Biosimilar
ANTIBODY DRUG CONJUGATES IN DEVELOPMENT
Figure 12
Rituxan/MabTheras Biosimilar
EXPRESSION SYSTEM USED FOR MANUFACTURE OF APPROVED DRUGS

List Of Figures

Table 1
Rituxan/MabTheras Biosimilar
BIOLOGICS PATENT EXPIRY TILL 2017
Table 2
Rituxan/MabTheras Biosimilar
BIOSIMILAR PIPELINE
Table 3
Rituxan/MabTheras Biosimilar
PRICE DIFFERENCE BETWEEN REFERENCE PRODUCTS AND BIOSIMILARS
Table 4
Rituxan/MabTheras Biosimilar
RITUXIMAB PATENT EXPIRIES
Table 5
Rituxan/MabTheras Biosimilar
PROJECTED RITUXIMAB SALES TILL 2017
Table 6
Rituxan/MabThera_Biosimilar
COMPETITION FROM KEY MARKETED DRUGS
Table 7
Rituxan/MabTheras Biosimilar
EFFICACY TARGET PROFILE OF GA101 IN CLINICAL STUDIES
Table 8
Rituxan/MabTheras Biosimilar
OBINUTUZUMAB: PHIII CLINICAL STUDY
Table 9
Rituxan/MabTheras Biosimilar
OBINUTUZUMAB: PHI/II CLINICAL STUDY
Table 10A
Rituxan/MabTheras Biosimilar
RITUXIMAB DEVELOPMENT PROGRAMS - IMMUNOLOGY
Table 10B
Rituxan/MabTheras Biosimilar
RITUXIMAB DEVELOPMENT PROGRAMS - ONCOLOGY
Table 11
Rituxan/MabTheras Biosimilar
COMPETITIVE LANDSCAPE RITUXIMAB
Table 12
Rituxan/MabTheras Biosimilar
SELECT RA DRUGS IN DEVELOPMENT
Table 13
Rituxan/MabTheras Biosimilar
ANALYTICAL ATTRIBUTES FOR CHARACTERIZATION OF BIOSIMILAR
Table 14
Rituxan/MabTheras Biosimilar
FDA APPROVED PRODUCTS USING ANIMAL/YEAST ALTERNATIVE EXPRESSION SYSTEM
Table 15
Rituxan/MabTheras Biosimilar
MABS EVOLUTION OF TECHNOLOGIES- FROM MOUSE TO HUMAN

Bed And Breakfast Accommodation Market Global Report 2017

The global bed and breakfast market was estimated to be around $9 billion as of 2016. The global hotel and motel made up around 1.5% of the overall hotel andother

USD 4000View Report

Hospitality Market Global Report 2017

Asia was the largest region in the hospitality market in 2016, accounting for around 38% market share. This can be attributed to high demand for food and beverage services, hotel

USD 6000View Report

RV (Recreational Vehicle) Parks And Campgrounds Market Global Report 2017

The global recreational vehicle parks and campgrounds market was estimated to be around $30 billion as of 2016. The global recreational vehicle parks and campgrounds made up around 66% of

USD 4000View Report

Bed And Breakfast Accommodation Market Global Report 2017

The global bed and breakfast market was estimated to be around $9 billion as of 2016. The global hotel and motel made up around 1.5% of the overall hotel andother

USD 4000View Report

Hospitality Market Global Report 2017

Asia was the largest region in the hospitality market in 2016, accounting for around 38% market share. This can be attributed to high demand for food and beverage services, hotel

USD 6000View Report

RV (Recreational Vehicle) Parks And Campgrounds Market Global Report 2017

The global recreational vehicle parks and campgrounds market was estimated to be around $30 billion as of 2016. The global recreational vehicle parks and campgrounds made up around 66% of

USD 4000View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 2000
  • Site Licence    $ 4000
  • Enterprisewide Licence    $ 6000
$ 2000

Reports Details

Published Date : Oct 2013
No. of Pages :45
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
paykasa bozdurma,paykasa bozdurma,astropay bozdurma,paykasa,paykasa,paykasa bozdurma,paykasa,astropay bozdurma,justin kart,bitcoin bozdurma,paykasa bozum,paykasa kart bozdurma,
beylikduzu escort,bahçeşehir escort,escort istanbul,
kartal escort,
seo teknikleri wordpress ücretsiz tema istanbul sexs shop hacklink e sigara sexs shop